TARGT Lung Liquid (Advanced)

A Comprehensive Liquid Biopsy-based Lung Cancer Gene Panel

TARGT Lung Liquid (Advanced) is an Advanced NGS-based lung cancer-targeted gene panel with NCCN and FDA-approved targetable genomic alterations.

This panel includes the Comprehensive Genomic Profiling of Liquid biopsy (ctDNA) by assessing four major categories of genomic alterations: SNVs/InDels, CNAs, and Gene Fusions/Splice Variant by profiling 15 known genes, which provide the most comprehensive and therapeutically valuable insights on Treatment monitoring, Quantification of Disease Burden, MRD status, and Disease Surveillance of the Lung cancer patient.

SNVs/InDels Coverage in TARGT Lung Liquid (Advanced)

ALK ERBB2 KRAS NRG2* NTRK3*

CNAs Coverage in TARGT Lung Liquid (Advanced)

BRAF FGFR2 MET NTRK1 RET

Gene Fusions Coverage in TARGT Lung Liquid (Advanced)

EGFR FGFR3 NRG1* NTRK2* ROS1

*Note – The scope of test includes the most common gene fusion for NRG1, NRG2, NTRK2 and NTRK3 with different transcripts – NACC2-NTRK2, TRIM24-NTRK2, QKI-NTRK2, BTBD1-NTRK3, EML4-NTRK3, ETV6-NTRK3, CD74-NRG1, SDC4-NRG1 & CD74-NRG2

Benefits of TARGT Lung Liquid (Advanced) Gene Panel Testing

Targeted analysis for lung cancer

TARGT Lung Liquid (Basic) gene panel focuses specifically on lung cancer, offering a comprehensive evaluation of genomic markers associated with the disease.

NCCN and FDA-approved targetable alterations

The gene panel includes genomic markers that NCCN and the FDA approve as actionable targets in lung cancer. By detecting these approved alterations, this panel enables oncologists to make informed treatment decisions based on established guidelines and approved therapies, enhancing the likelihood of positive treatment outcomes.

Liquid biopsy (ctDNA) assessment

The gene panel utilizes liquid biopsy, specifically circulating tumor DNA (ctDNA) analysis, for genomic profiling.

Clinically Actionable Insights

The gene panel provides oncologists with clinically actionable insights from patients’ peripheral blood. The detailed genetic information obtained through this gene panel testing allows oncologists to make informed treatment decisions.

Why Choose 4baseCare's TARGT Lung Liquid (Advanced) Cancer Gene Panel?

Comprehensive Analysis

Our Cancer Gene Panel thoroughly assesses clinically relevant genes, ensuring accurate and reliable results.

Advanced Technology

We utilize cutting-edge genomic sequencing technologies to deliver precise and detailed genetic information.

Expert Team

Our team of experienced genetic counselors and healthcare professionals will guide you through the testing process, answer your questions, and help you understand the implications of the results.

Liquid Biopsy Cancer Gene Panels